Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 8 Gy Clear all
Completed Phase 2 Interventional Results available

Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer

NCT00387127
View directory record Official record
Conditions
Neoplasms, Head and Neck
Interventions
Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Minneapolis, Minnesota • Kansas City, Missouri • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 31, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

NCT01319565
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI)
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 31, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Results available

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

NCT03835533
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B), CDX-301 (Cohort B and C), Poly-ICLC (Cohort B), INO-5151 (Cohort C), Cellectra 2000
Drug · Radiation · Device
Lead sponsor
Parker Institute for Cancer Immunotherapy
Other
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 31, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer

NCT00308516
View directory record Official record
Conditions
Rectal Cancer, Cancer of the Rectum, Colorectal Cancer
Interventions
5-Fluorouracil, Bevacizumab, Radiation Therapy, Oxaliplatin, Leucovorin
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
14
States / cities
Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 31, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

NCT00513604
View directory record Official record
Conditions
Melanoma, Malignant Melanoma, Melanoma, Experimental, Experimental Melanomas
Interventions
aldesleukin, therapeutic autologous lymphocytes, Cyclophosphamide, Fludarabine phosphate, Total body irradiation
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 31, 2026, 9:34 PM EDT
Terminated Phase 1 Interventional Results available

A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT00787852
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47, Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38
Drug
Lead sponsor
Brown University
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Oct 31, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT01218048
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Cetuximab, Surgery, Post-surgical radiation, Cisplatin or carboplatin
Drug · Procedure · Radiation
Lead sponsor
Robert Ferris
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 31, 2026, 9:34 PM EDT
Recruiting Phase 2 Interventional

Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas

NCT05419518
View directory record Official record
Conditions
Neoplasm Metastases, Metastases, Neoplasm
Interventions
EXTERNAL BEAM RADIATION
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Hamilton, New Jersey • Lakewood, New Jersey • Livingston, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 31, 2026, 9:34 PM EDT
Completed Phase 1 Interventional

Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC

NCT05053737
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Atezolizumab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Highlands Ranch, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 31, 2026, 9:34 PM EDT
Terminated Phase 2 Interventional Results available

Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy

NCT00766636
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Radiation Therapy, Erlotinib, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 31, 2026, 9:34 PM EDT
Recruiting Phase 2 Interventional

Converting HR+ Breast Cancer Into an Individualized Vaccine

NCT03804944
View directory record Official record
Conditions
Breast Cancer
Interventions
Focal Radiation therapy, Pembrolizumab (200mg IV for 30 minutes, CDX-301
Radiation · Drug · Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Los Angeles, California • New York, New York • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 31, 2026, 9:34 PM EDT
Active, not recruiting Phase 3 Interventional

Palliative UNConventional Hypofractionation Trial for Metastatic Bone Disease

NCT05115331
View directory record Official record
Conditions
Metastatic Bone Tumor
Interventions
Experimental Radiation Dose, Conventional Radiation Dose
Radiation
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 31, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors

NCT00763750
View directory record Official record
Conditions
Brain Tumor
Interventions
PPX +TMZ+XRT
Drug
Lead sponsor
howard safran
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 31, 2026, 9:34 PM EDT
Terminated Not applicable Interventional Results available

Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma

NCT02138578
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
SBRT, RFA
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 31, 2026, 9:34 PM EDT
Active, not recruiting Phase 2 Interventional

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

NCT03646617
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Hypofractionated Radiation Therapy (HFRT), Nivolumab, Ipilimumab
Radiation · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Lancaster, Pennsylvania • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT02186847
View directory record Official record
Conditions
Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Interventions
Radiation Therapy, Carboplatin, Metformin, Paclitaxel
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
219
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Auburn, California + 176 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 31, 2026, 9:34 PM EDT
Recruiting No phase listed Observational

GammaPod Registry and Quality of Life Nomogram

NCT03562273
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Quality Of Life Sizing Nomogram
Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
4
States / cities
Bel Air, Maryland • Columbia, Maryland • Glen Burnie, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 31, 2026, 9:34 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation

NCT04030000
View directory record Official record
Conditions
Uterine Carcinoma
Interventions
Paclitaxel/Carboplatin, Pelvic radiation therapy
Drug · Radiation
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 99 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 31, 2026, 9:34 PM EDT
Completed Phase 4 Interventional Results available

Stereotactic Body Radiotherapy for Head and Neck Tumors

NCT01344356
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma, Paraganglioma of Head and Neck, Chordoma of Head and Neck, Chondrosarcoma of Head and Neck, Angiofibroma of Head and Neck
Interventions
Stereotactic body radiotherapy
Radiation
Lead sponsor
Mercy Research
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 31, 2026, 9:34 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT01368588
View directory record Official record
Conditions
Prostate Cancer
Interventions
three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
454
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 31, 2026, 9:34 PM EDT
Completed Phase 1 Interventional

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

NCT02903069
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma
Interventions
MRZ, TMZ, RT, Optune
Drug · Radiation · Device
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
La Jolla, California • Orange, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 31, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Results available

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

NCT01300572
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Secondary Acute Myeloid Leukemia
Interventions
Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Indium In 111 Anti-CD45 Monoclonal Antibody BC8, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Total-Body Irradiation, Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
Procedure · Drug · Biological + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 31, 2026, 9:34 PM EDT
Terminated Phase 2 Interventional

PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer

NCT02910882
View directory record Official record
Conditions
Pancreatic Adenocarcinoma Non-resectable
Interventions
PEGylated Recombinant Human Hyaluronidase (PEGPH20), Gemcitabine, Radiation
Drug · Radiation
Lead sponsor
Scripps Health
Other
Eligibility
Up to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 31, 2026, 9:34 PM EDT
Completed Phase 1 Interventional

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

NCT02639026
View directory record Official record
Conditions
Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
Interventions
Radiotherapy, MEDI4736, Tremelimumab
Radiation · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 31, 2026, 9:34 PM EDT